Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 23562518)

1.

The effect of dopamine on MPTP-induced rotarod disability.

Ayton S, George JL, Adlard PA, Bush AI, Cherny RA, Finkelstein DI.

Neurosci Lett. 2013 May 24;543:105-9. doi: 10.1016/j.neulet.2013.02.066. Epub 2013 Apr 2.

PMID:
23562518
2.

Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.

Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS.

Neuroscience. 2001;106(3):589-601.

PMID:
11591459
3.

Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.

Haobam R, Sindhu KM, Chandra G, Mohanakumar KP.

Behav Brain Res. 2005 Sep 8;163(2):159-67.

PMID:
15941598
4.
5.

Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

L'Episcopo F, Tirolo C, Caniglia S, Testa N, Serra PA, Impagnatiello F, Morale MC, Marchetti B.

J Neuroinflammation. 2010 Nov 23;7:83. doi: 10.1186/1742-2094-7-83.

6.

Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity.

Fornai F, Battaglia G, Gesi M, Giorgi FS, Orzi F, Nicoletti F, Ruggieri S.

Brain Res. 2000 Dec 22;887(1):110-7.

PMID:
11134595
7.

Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Schumm S, Sebban C, Cohen-Salmon C, Callebert J, Launay JM, Golmard JL, Boussicault L, Petropoulos I, Hild A, Rousselet E, Prigent A, Friguet B, Mariani J, Hirsch EC.

J Neurochem. 2012 Sep;122(5):1032-46. doi: 10.1111/j.1471-4159.2012.07837.x. Epub 2012 Jul 11.

PMID:
22708926
9.
11.

alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.

Bazzu G, Calia G, Puggioni G, Spissu Y, Rocchitta G, Debetto P, Grigoletto J, Zusso M, Migheli R, Serra PA, Desole MS, Miele E.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):482-90. Review.

PMID:
20522009
12.
13.

Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease.

Antzoulatos E, Jakowec MW, Petzinger GM, Wood RI.

Pharmacol Biochem Behav. 2010 Jun;95(4):466-72. doi: 10.1016/j.pbb.2010.03.009. Epub 2010 Mar 27.

14.

The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.

Rozas G, López-Martín E, Guerra MJ, Labandeira-García JL.

J Neurosci Methods. 1998 Sep 1;83(2):165-75.

PMID:
9765130
15.
16.

Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.

Mori A, Ohashi S, Nakai M, Moriizumi T, Mitsumoto Y.

Neurosci Res. 2005 Mar;51(3):265-74. Epub 2005 Jan 8.

PMID:
15710490
17.
18.
19.
20.

A rotarod test for evaluation of motor skill learning.

Shiotsuki H, Yoshimi K, Shimo Y, Funayama M, Takamatsu Y, Ikeda K, Takahashi R, Kitazawa S, Hattori N.

J Neurosci Methods. 2010 Jun 15;189(2):180-5. doi: 10.1016/j.jneumeth.2010.03.026. Epub 2010 Mar 30.

PMID:
20359499
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk